JP2024530007A - 精神活性医薬品ならびに精神医学的および神経学的な病態および障害の治療のためのそれらの使用 - Google Patents

精神活性医薬品ならびに精神医学的および神経学的な病態および障害の治療のためのそれらの使用 Download PDF

Info

Publication number
JP2024530007A
JP2024530007A JP2024506546A JP2024506546A JP2024530007A JP 2024530007 A JP2024530007 A JP 2024530007A JP 2024506546 A JP2024506546 A JP 2024506546A JP 2024506546 A JP2024506546 A JP 2024506546A JP 2024530007 A JP2024530007 A JP 2024530007A
Authority
JP
Japan
Prior art keywords
disorder
disorders
methylone
anxiety
dose
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024506546A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024530007A5 (https=
Inventor
マンデル，ブレイク
ストグニエフ，マーティン
ルイーズ シュミット，ジェニファー
シーリグ，マーカス
Original Assignee
トランセンド セラピューティクス，インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by トランセンド セラピューティクス，インコーポレイテッド filed Critical トランセンド セラピューティクス，インコーポレイテッド
Publication of JP2024530007A publication Critical patent/JP2024530007A/ja
Publication of JP2024530007A5 publication Critical patent/JP2024530007A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
    • A61K31/36—Compounds containing methylenedioxyphenyl groups, e.g. sesamin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
JP2024506546A 2021-08-06 2022-08-01 精神活性医薬品ならびに精神医学的および神経学的な病態および障害の治療のためのそれらの使用 Pending JP2024530007A (ja)

Applications Claiming Priority (11)

Application Number Priority Date Filing Date Title
US202163230237P 2021-08-06 2021-08-06
US63/230,237 2021-08-06
US202163240113P 2021-09-02 2021-09-02
US63/240,113 2021-09-02
US202163255706P 2021-10-14 2021-10-14
US63/255,706 2021-10-14
US202263325757P 2022-03-31 2022-03-31
US63/325,757 2022-03-31
US202263328343P 2022-04-07 2022-04-07
US63/328,343 2022-04-07
PCT/US2022/074369 WO2023015154A1 (en) 2021-08-06 2022-08-01 Psychoactive medicines and their use for treating psychiatric and neurological conditions and disorders

Publications (2)

Publication Number Publication Date
JP2024530007A true JP2024530007A (ja) 2024-08-14
JP2024530007A5 JP2024530007A5 (https=) 2025-08-06

Family

ID=85156410

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024506546A Pending JP2024530007A (ja) 2021-08-06 2022-08-01 精神活性医薬品ならびに精神医学的および神経学的な病態および障害の治療のためのそれらの使用

Country Status (10)

Country Link
US (6) US11707446B2 (https=)
EP (1) EP4380588A4 (https=)
JP (1) JP2024530007A (https=)
KR (1) KR20240072133A (https=)
AU (1) AU2022325135A1 (https=)
CA (1) CA3227360A1 (https=)
IL (1) IL310334A (https=)
MX (1) MX2024001654A (https=)
TW (1) TW202327571A (https=)
WO (1) WO2023015154A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024254190A2 (en) * 2023-06-06 2024-12-12 Transcend Therapeutics, Inc. Psychoactive medicines and their use for treating psychiatric and neurological conditions and disorders
US12295937B2 (en) 2021-08-06 2025-05-13 Transcend Therapeutics, Inc. Psychoactive medicines and their use for treating psychiatric and neurological conditions and disorders
US12343326B2 (en) 2021-08-06 2025-07-01 Transcend Therapeutics, Inc. Psychoactive medicines and their use for treating psychiatric and neurological conditions and disorders
MX2024001654A (es) 2021-08-06 2024-06-28 Transcend Therapeutics Inc Medicamentos psicoactivos y su uso para el tratamiento de enfermedades y trastornos psiquiatricos y neurologicos.
KR20240165982A (ko) * 2022-03-31 2024-11-25 트랜센드 테라퓨틱스 인코퍼레이티드 향정신성 의약품과 정신 및 신경계 병태 및 장애를 치료하기 위한 이의 용도

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996039133A1 (en) * 1995-06-06 1996-12-12 Neurobiological Technologies, Inc. Novel n-substituted-2-amino-3',4'-methylene-dioxypropiophenones
US8575194B1 (en) 2004-08-31 2013-11-05 Jack William Schultz Treatment methods of cognitive, emotional and mental ailments and disorders
US20120108510A1 (en) 2010-05-20 2012-05-03 Emory University Methods of improving behavioral therapies
EP2931291B1 (en) 2012-12-11 2021-10-20 The McLean Hospital Corporation Xenon treatment as an adjunct to psychotherapy for psychiatric disorders
WO2017151980A1 (en) 2016-03-03 2017-09-08 Segreti Louis M Cannabis-based bioactive formulations and methods for use thereof
WO2021257500A1 (en) 2020-06-17 2021-12-23 Lobe Sciences Ltd. Methods and compositions for treating mild traumatic brain injury, post-traumatic stress disorder and mild traumatic brain injury with post traumatic stress disorder
JP2024512796A (ja) * 2021-04-01 2024-03-19 テラン バイオサイエンシーズ インク． サイケデリック薬およびセロトニン受容体調節因子に関する方法と組成物
MX2024001654A (es) 2021-08-06 2024-06-28 Transcend Therapeutics Inc Medicamentos psicoactivos y su uso para el tratamiento de enfermedades y trastornos psiquiatricos y neurologicos.
EP4426685A4 (en) * 2021-11-05 2026-01-07 Terran Biosciences Inc Isotopic salts, crystalline forms, stereoisomers of methylone and ethylone and their methods of use

Also Published As

Publication number Publication date
US20240058301A1 (en) 2024-02-22
WO2023015154A1 (en) 2023-02-09
US20240293357A1 (en) 2024-09-05
EP4380588A1 (en) 2024-06-12
US11969407B2 (en) 2024-04-30
US20230054211A1 (en) 2023-02-23
TW202327571A (zh) 2023-07-16
US12059402B2 (en) 2024-08-13
US20250255846A1 (en) 2025-08-14
CA3227360A1 (en) 2023-02-09
KR20240072133A (ko) 2024-05-23
US11707446B2 (en) 2023-07-25
US12233046B2 (en) 2025-02-25
IL310334A (en) 2024-03-01
EP4380588A4 (en) 2025-10-08
US20260083699A1 (en) 2026-03-26
MX2024001654A (es) 2024-06-28
US20230338333A1 (en) 2023-10-26
AU2022325135A1 (en) 2024-02-08

Similar Documents

Publication Publication Date Title
JP2024530007A (ja) 精神活性医薬品ならびに精神医学的および神経学的な病態および障害の治療のためのそれらの使用
AU2011313814B2 (en) Combination therapy for the treatment of depression and other non-infectious diseases
AU2023336222A1 (en) Use of mdma for treatment of stress-related disorders
JP2025510790A (ja) 精神活性医薬品ならびに精神医学的および神経学的な病態および障害の治療のためのそれらの用途
US20250221957A1 (en) Psychoactive medicines and their use for treating psychiatric and neurological conditions and disorders
US12343326B2 (en) Psychoactive medicines and their use for treating psychiatric and neurological conditions and disorders
US12295937B2 (en) Psychoactive medicines and their use for treating psychiatric and neurological conditions and disorders
HK40112015A (zh) 精神作用药物及其用於治疗精神和神经病状和病症的用途
US20250332139A1 (en) Psychoactive medicines and their use for treating psychiatric and neurological conditions and disorders
HK40120411A (zh) 精神作用药物及其用於治疗精神和神经病状和病症的用途
EP4724433A2 (en) Psychoactive medicines and their use for treating psychiatric and neurological conditions and disorders
WO2024254190A2 (en) Psychoactive medicines and their use for treating psychiatric and neurological conditions and disorders
JP2024508372A (ja) 注意欠陥／多動性障害の治療又は予防に使用するための化合物
CN118434416A (zh) 精神作用药物及其用于治疗精神和神经病状和病症的用途
KR20260053276A (ko) 향정신성 의약품과 정신 및 신경계 병태 및 장애를 치료하기 위한 이의 용도
JP2024538015A (ja) 治療抵抗性うつ病を含むうつ病の治療のための２－フルオロデスクロロケタミン
HK40101538B (en) Compounds for use in the treatment of attention deficit hyperactivity disorder
RU2450822C1 (ru) Применение гептапептида для лечения болезни паркинсона и способ лечения такой болезни
TW200529858A (en) Novel use

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240628

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250729

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20250729